PROCEPT BioRobotics (PRCT) experienced a significant after-hours plunge of 28.23% on Wednesday.
The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which fell short of analyst expectations. PROCEPT reported a quarterly loss per share of $(0.53), missing the consensus estimate of $(0.32) by a wide margin. Revenue for the quarter was $76.383 million, also below the estimated $94.137 million. Furthermore, the company's adjusted EBITDA loss of $19.013 million was significantly worse than the anticipated loss of $2.8 million.
While the company reported a year-over-year sales increase and provided a revenue growth outlook of 27-33% for the full year 2026, the substantial misses on key quarterly metrics appear to have driven the negative investor reaction in the extended trading session.